Vertex Pharmaceuticals (VRTX) swung to profitability as the company left behind five years of annual earnings declines ...

The stock of niche financial software company Vertex ( VERX 4.13%) didn't get a very good start to the trading week at all.

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) will be announcing earnings results this Monday after market hours. Here’s what you need to know.

Vertex Pharmaceuticals (VRTX) is rated as a "Strong Buy" due to robust revenue growth and multiple expansion opportunities ...

The potential approval of Vertex’s IgAN therapy povetacicept in 2026 comes amid launch headwinds for the company’s non-opioid ...

One key figure, however, indicates otherwise as sales for Journavx were at $20 million for the period, coming up $3 million ...

Vertex stock dipped Tuesday on a mixed third-quarter report, with the lion's share of its sales beat coming from its older ...

Fintel reports that on November 4, 2025, Needham maintained coverage of Vertex (NasdaqGM:VERX) with a Buy recommendation.

Analysts expect Vertex Pharmaceuticals to report an earnings per share (EPS) of $4.35. Investors in Vertex Pharmaceuticals are eagerly awaiting the company's announcement, hoping for news of ...

The stock, which is down more than 61% in 2025, sold off after reporting a Q3 EPS beat missing on revenue expectations.

Boston-based Vertex reported revenue of $3.08 billion, an 11 percent gain from one year ago. That was ahead of analysts’ ...